[The use of sorbent "Sillard" in comprehensive treatment of patients with hemophilia and purulent-inflammatory complications].
An applicational usage of a siliconcontaining sorpent "Sillard" in the complex of treatment of patients with hemophilia, suffering inflammatory-purulent complications, had promoted the shortening of the wound clearance duration by 2-3 days and of the patient stationary treatment--by 3-4 days.
D000038:Abscess / Q000150:complications* / Q000382:microbiology; D000273:Adipose Tissue; D000293:Adolescent; D000328:Adult; D000681:Amylases / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000382:microbiology; D002481:Cellulitis / Q000150:complications* / Q000382:microbiology; D003131:Combined Modality Therapy; D004338:Drug Combinations; D016061:Enterosorption / Q000379:methods; D006090:Gram-Negative Bacteria / Q000302:isolation & purification; D006094:Gram-Positive Bacteria / Q000302:isolation & purification; D006467:Hemophilia A / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D008297:Male; D010447:Peptide Hydrolases / Q000627:therapeutic use*; D011136:Polysorbates / Q000627:therapeutic use*